P0845: Safety and Adverse Events of the Adjuvanted Herpes Zoster Vaccine (Shingrix) in Inflammatory Bowel Disease Patients: A Comparison of Age Groups Under and Over 50 YearsECCO'25Year: 2025
Authors: Kim , D.H.(1);Kang , S.B.(2)*;Park , Y.H.(3);Kim , K.O.(4);Park , S.H.(5);Lee , Y.J.(6);Moon , W.(7);Park , S.J.(8);Na , S.Y.(9);Kim , E.S.(10);Oh , S.J.(11);Shin , S.Y.(12);
(1)Chonnam National University Hospital, Division of gastroenterology- Department of Internal medicine and Inflammatory Bowel disease Clinic, Gwnagju, Korea- Republic Of;(2)Daejeon St. Mary’s Hospital- College of Medicine- The Catholic University of Korea, Division of Gastroenterology- Department of Internal Medicine, Daejeon, Korea- Republic Of;(3)Ewha Womans University College of Medicine, Department of Internal Medicine, Seoul, Korea- Republic Of;(4)Yeungnam University College of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(5)Asan Medical Center- University of Ulsan College of Medicine, Department of Gastroenterology, Seoul, Korea- Republic Of;(6)Keimyung University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(7)Kosin University College of Medicine, Department of Internal Medicine, Busan, Korea- Republic Of;(8)Severance Hospital- Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, Korea- Republic Of;(9)Incheon St. Mary's Hospital- College of Medicine- The Catholic University of Korea, Department of Internal Medicine, Incheon, Korea- Republic Of;(10)Korea University College of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Seoul, Korea- Republic Of;(11)Kyung Hee University Hospital- Kyung Hee University College of Medicine, Department of Gastroenterology- Center for Crohn's and Colitis, Seoul, Korea- Republic Of;(12)Chung-Ang University College of Medicine, Department of Internal Medicine, Seoul, Korea- Republic Of; IBD research group of KASID (Korean Association for the Study of Intestinal Diseases)
References
1. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med 2013;369:255-263.
2. Marra F, Parhar K, Huang B, Vadlamudi N. Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis 2020;7:ofaa005.
3. Imafuku S, Dormal G, Goto Y, Jégou C, Rosillon D, Matsuki T. Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: Results from a claims database cohort study, from 2005 to 2014. J Dermatol 2020;47:236-244.
4. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1483-1490.
5. Matsuoka K, Togo K, Yoshii N, Hoshi M, Arai S. Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis. Intest Res 2023;21:88-99.
6. Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:37.
7. Harbecke R, Cohen JI, Oxman MN. Herpes Zoster Vaccines. J Infect Dis 2021;224:S429-s442.
8. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010;51:197-213.
9. James SF, Chahine EB, Sucher AJ, Hanna C. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine. Ann Pharmacother 2018;52:673-680.
10. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-1349.
11. Khan N, Patel D, Trivedi C, et al. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 2018;16:1919-1927.e1913.
P0846: A patient’s perspective on the use of exclusive enteral nutrition (EEN) for the treatment of paediatric Crohn's Disease.ECCO'25Year: 2025
Authors: Martin, A.(1);O'meara, M.(2)*;
(1)University College Dublin, School of Human Nutrition, Dublin, Ireland;(2)Childrens Health Ireland at Crumlin, Dietetic Department, Dublin, Ireland;
P0847: Comparative efficacy on steroid-free remission of pharmacological therapies for moderate-to-severe Ulcerative Colitis: A systematic review and network meta-analysisECCO'25Year: 2025
Authors: Katsoula, A.(1,2)*;Paschos, P.(2,3);Malandris, K.(2);Giouleme, O.(1);Tsapas, A.(2,4);
(1)Aristotle University of Thessaloniki, Hippokration Hospital- Gastroenterology Division-Second Propaedeutic Department of Internal Medicine- Medical School- Aristotle University of Thessaloniki, Thessaloniki, Greece;(2)Clinical Research and Evidence-Based Medicine Unit, Second Medical Department- Aristotle University of Thessaloniki, Thessaloniki, Greece;(3)“Papageorgiou” Hospital, First Department of Internal Medicine, Thessaloniki, Greece;(4)Harris Manchester College, University of Oxford, Oxford, United Kingdom; This study was funded by a research grant 2020EOMIFNEp5 from the Hellenic Group for the Study of IBD (EOMIFNE)
P0848: Engineering and Development of a Novel Bispecific Antibody Targeting both TL1A and α4β7 for the Treatment of IBDECCO'25Year: 2025
Authors: Ran, H.(1);Huang, J.(1);Zhang, X.(1);Li, S.(1);Su, C.(1);Chen, C.(1);Liu, D.(1);Xu, X.(1);Chen, X.(1);Fei, K.(1);Tian, L.(1);Peng, J.(1);Zhu, Z.(1)*;
(1)Helixon Therapeutics, Drug discovery, New York, United States;
P0849: Real-world efficacy and safety of filgotinib in ulcerative colitis: results from the ENEIDA registryECCO'25Year: 2025
Authors: Rodríguez-Lago, I.(1)*;Cudero, L.(2);Martínez Pascual, C.(3);Mínguez, A.(4);Ferreiro-Iglesias, R.(5);Arranz, L.(6);Royo, A.M.(7);Martín-Rodríguez, D.(8);Mejías, M.D.L.Á.(9);Calafat, M.(10);Calvo, M.(11);Gargallo-Puyuelo, C.J.(12);Granja, A.(13);Santos-Fernández, J.(14);Ucha, P.(15);Ceballos, D.(16);Martín-Arranz, M.D.(17);Ferrer, I.(18);Ramos, L.(19);Almela, P.(20);Fernández-Clotet, A.(21);García-Bosch, O.(22);Huguet, J.M.(23);Lozano, M.L.(24);Riestra, S.(25);Sese, E.(26);Torres, G.(27);Trapero , A.M.(28);Varela, P.(29);Domènech, E.(10);Barreiro-de Acosta, M.(5);
(1)Hospital Universitario de Galdakao, Department of Gastroenterology, Galdakao, Spain;(2)Hospital Universitario 12 de Octubre, Gastroenterology Department, Madrid, Spain;(3)Hospital Clínico Universitario Virgen de La Arrixaca, Hospital Clínico Universitario Virgen de La Arrixaca, Murcia, Spain;(4)Hospital Universitario y Politécnico La Fe, Gastroenterology Department, Valencia, Spain;(5)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology Department, Santiago de Compostela, Spain;(6)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology Department, La Laguna, Spain;(7)Hospital Universitario Miguel Servet, Gastroenterology Department, Zaragoza, Spain;(8)Hospital Infanta Cristina, Gastroenterology Department, Parla, Spain;(9)Hospital General Universitario de Ciudad Real, Gastroenterology Department, Ciudad Real, Spain;(10)Hospital Universitari Germans Trias i Pujol, Gastroenterology Department, Badalona, Spain;(11)Hospital Universitario Puerta de Hierro, Gastroenterology Department, Mahadahonda, Spain;(12)Hospital Clínico Universtario Lozano Blesa, Gastroenterology Department, Zaragoza, Spain;(13)Hospital Universitario de Fuenlabrada, Gastroenterology Department, Fuenlabrada, Spain;(14)Complejo Asistencial Universitario de Palencia, Gastroenterology Department, Palencia, Spain;(15)Hospital Álvaro Cunqueiro, Gastroenterology Department, Vigo, Spain;(16)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Department, Las Palmas de Gran Canaria, Spain;(17)Hospital Universitario La Paz, Gastroenterology Department, Madrid, Spain;(18)Hospital de Manises, Gastroenterology Department, Manises, Spain;(19)Hospital Universitario de Canarias, Gastroenterology Department, La laguna, Spain;(20)Hospital General Universitario de Castellón, Gastroenterology Department, Castellón, Spain;(21)Hospital Clinic de Barcelona, Gastroenterology Department, Barcelona, Spain;(22)Hospital de Sant Joan Despí Moisés Broggi, Gastroenterology Department, Sant Joan Despí, Spain;(23)Hospital General Universitario de Valencia, Gastroenterology Department, Valencia, Spain;(24)Hospital Universitario de Cáceres, Gastroenterology Department, Cáceres, Spain;(25)Hospital Universitario Central de Asturias, Gastroenterology Department, Oviedo, Spain;(26)Hospital Universitari Arnau de Vilanova, Gastroenterology Department, Lleida, Spain;(27)Hospital General de Granollers, Gastroenterology Department, Granollers, Spain;(28)Hospital Universitario de Jaén, Gastroenterology Department, Jaén, Spain;(29)Hospital Universitario de Cabueñes, Gastroenterology Department, Gijón, Spain; on behalf of the ENEIDA registry of GETECCU
P0850: Managing pain in people with Crohn's Disease: feasibility testing of an Acceptance and Commitment Group Therapy intervention.ECCO'25Year: 2025
Authors: Watson, N.(1)*; Mawdsley , J.(2);Kent , A.(3);Duff , A.(4);Norton , C.(5);Moulton, C.(6); Czuber-Dochan , W.(7);
(1)King's college London, Faculty of Nursing- Midwifery & Palliative Care, London, United Kingdom;(2)St Thomas’ Hospital, Department of Gastroenterology, London, United Kingdom;(3)King's college hospital, Department Gastroenterology, London, United Kingdom;(4)St Thomas’ Hospital, Department Gastroenterology, London, United Kingdom;(5)Kings College London, Faculty of Nursing- Midwifery & Palliative Care, London, United Kingdom;(6)Central Middlesex Hospital, Psychological Medicine Unit, London, United Kingdom;(7)King’s College London, Faculty of Nursing- Midwifery & Palliative Care, London, United Kingdom;
1 Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006;12(1):38-46. doi:10.1097/01.mib.0000195391.49762.89
2 Feliu-Soler A, Montesinos F, Gutiérrez-Martínez O, Scott W, McCracken LM, Luciano JV. Current status of acceptance and commitment therapy for chronic pain: a narrative review. J Pain Res. 2018;11:2145-2159. Published 2018 Oct 2. doi:10.2147/JPR.S144631
P0851: Managing tuberculosis infection risk in inflammatory bowel disease patients before biological therapy initiation – Single-center experienceECCO'25Year: 2025
Authors: Toplicanin, A.(1)*;Vuksanovic, S.(1);Spiric-Milovancevic, J.(1);Nikolic, A.(1);Zgradic, S.(1);Toncev, L.(1);Dragasevic, S.(1,2);Jovicic, I.(1);Djuranovic, S.(1,2);Pavlović-Marković, A.(1,2);Popovic, D.(1,2);Perovic, V.(3);Popadic, D.(3);Sokic Milutinovic, A.(1,2);
(1)University Clinical Center of Serbia, Clinic for gastroenterohepatology, Belgrade, Serbia;(2)University of Belgrade, School of Medicine, Belgrade, Serbia;(3)University of Belgrade, Faculty of Medicine- Institute of Microbiology and Immunology, Belgrade, Serbia;
1. Jin BC, Moon HJ, Kim SW. Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease. The Korean Journal of Gastroenterology. 2022;80(2):72-76. doi:https://doi.org/10.4166/kjg.2022.086
2. Beaugerie L, Rahier JF, Kirchgesner J. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020;18(6):1324-1335.e2. doi:10.1016/j.cgh.2020.02.009
3. Choi MG, Ye BD, Yang SK, Shim TS, Jo KW, Park SH. The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea. J Korean Med Sci. 2022;37(14):e107. Published 2022 Apr 11. doi:10.3346/jkms.2022.37.e107
4. Godfrey MS, Friedman LN. Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-α and Beyond. Clin Chest Med. 2019;40(4):721-739. doi:10.1016/j.ccm.2019.07.003
P0852: Influence of a gluten-free dietary intervention on the gut microbiome and inflammation in inflammatory bowel disease: results from murine experiments and protocol of a prospective proof-of-concept human study as part of the miGut-Health projectECCO'25Year: 2025
Authors: Hübener, S.(1)*;Stallbaum, F.(1);Machicote, A.(1);Steglich, B.(1);Oguz-Coeloglu, Z.(1);Jagemann, B.(2);Schramm, C.(1);Huber, S.(1);
(1)University Medical Center Hamburg-Eppendorf, I. Department of Medicine, Hamburg, Germany;(2)University Medical Center Hamburg-Eppendorf, Institute of Health Care Research in Dermatology and Nursing IVDP, Hamburg, Germany;
1. Liwinski T, Hübener S, Henze L, et al. A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis. Aliment Pharmacol Ther. 2023;57(2):224-236. doi:10.1111/apt.17256
P0853: Decrease in fecal calprotectin and C-reactive protein levels correlate with improved clinical outcomes in patients with moderately to severely active Crohn’s disease treated with mirikizumabECCO'25Year: 2025
Authors: Charabaty , A.(1);Kayal , M.(2);Kelly , C.R.(3);Cohen , B.L.(4);D'Haens , G.(5);Hart , A.(6);Chan-Diehl , F.(7);Yu , G.(7)*;Brogan , Y.(8);Protic , M.(7);Moses , R.(7);Fisher , D.(7);Travis , S.(9);
(1)Johns Hopkins University, Division of Gastroenterology and Hepatology, Baltimore, United States;(2)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(3)Brigham and Women's Hospital, Department of Medicine, Boston, United States;(4)Cleveland Clinic Foundation, Department of Gastroenterology- Hepatology & Nutrition- Digestive Diseases Institute, Cleveland, United States;(5)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)St Mark's Hospital, IBD Unit, London, United Kingdom;(7)Eli Lilly and Company, Lilly Immunology, Indianapolis, United States;(8)Tigermed Group, Statistics, Hangzhou, China;(9)University of Oxford, Kennedy Institute and Translational Gastroenterology Unit, Oxford, United Kingdom;
- M Ferrante, S Danese, M Chen, et al. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study, Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i7–i9, https://doi.org/10.1093/ecco-jcc/jjad212.0005
P0854: The Effectiveness of Risankizumab as Induction Therapy for Crohn’s Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)ECCO'25Year: 2025
Authors: Macaluso, F.S.(1)*;Renna, S.(1);Fries, W.(2);Viola, A.(2);Cappello, M.(3);Salerno, I.A.(3);Mocciaro, F.(4);Scrivo, B.(4);Giangreco, E.(5);Ferracane, C.(6);Minissale, M.G.(7);Distefano, M.E.(8);Tortorella, V.(9);Termini, A.(1);Bertoncello, L.(1);Orlando, A.(1);
(1)"Villa Sofia-Cervello" Hospital, IBD Unit, Palermo, Italy;(2)"G. Martino" Hospital, IBD Unit, Messina, Italy;(3)University of Palermo, Gastroenterology & Hepatology Section- PROMISE, Palermo, Italy;(4)ARNAS Civico - Di Cristina – Benfratelli Hospital, Gastroenterology and Endoscopy Unit, Palermo, Italy;(5)“Guzzardi” Hospital, Gastroenterology Unit, Vittoria, Italy;(6)“Vittorio Emanuele” Hospital, Gastroenterology Unit, Catania, Italy;(7)A.O. ‘Buccheri La Ferla Fatebenefratelli’, Gastroenterology and Endoscopy Unit, Palermo, Italy;(8)"Cannizzaro” Hospital, IBD Unit, Catania, Italy;(9)A.O.O.R. ‘Papardo Piemonte’, Gastroenterology Unit, Messina, Italy; Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
P0855: Rise in admissions for Acute Severe Ulcerative Colitis at an Australian tertiary IBD centre with a culturally and linguistically diverse population: Implications for health resource planningECCO'25Year: 2025
Authors: Bartlett , R.(1);Mohamedrashed , M.(1);Yogakanthi , S.(1);Chew , M.(1);Nedumannil , L.(1);Pearce , R.(1);Lucas , S.(1);Chauhan , A.(1);Lewis , D.(1);Kashkooli , S.(1);Garg , M.(1)*;
(1)Northern Health, Gastroenterology, Melbourne, Australia;
P0856: Reasons for switching subcutaneous and oral advanced therapies for IBD: a single-centre experience.ECCO'25Year: 2025
Authors: Jackson, D.(1)*;Wilcox, S.(1);Hicks, L.(1);Dummer, S.(1);Evans, R.(1);Singh, J.(1);Henson, S.(1);Thomas, L.(1);Shakespeare, R.(1);Eadala , P.(1);Nagari, M.(1);
(1)NHS - Swansea Bay University Health Board, Gastroenterology, Swansea, United Kingdom;
P0857: The Effectiveness of Ustekinumab in Treating Small Bowel Crohn’s Disease Assessed by Magnetic Resonance EnterologyECCO'25Year: 2025
Authors: Wang, Y.(1)*;Nie, J.(1);Ren, Y.(2);Mao, R.(1);
(1)The First Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(2)Sun Yat-sen University, Zhongshan School of Medicine, Guangzhou, China;
P0858: Rate of participation in a second randomized clinical trial and factors associated with the likelihood of participation among inflammatory bowel disease patients who already experienced a randomized clinical trial.ECCO'25Year: 2025
Authors: Gabbiadini, R.(1)*;Pitoni, D.(1);Bertoli, P.(1);Privitera, G.(1);Dal Buono, A.(1);Danieli, P.(1);Bezzio, C.(1);Armuzzi, A.(1);
(1)IRCCS Humanitas Research Hospital, IBD Center- Department of Gastroenterology, Rozzano- Milan, Italy;
P0859: Handgrip Strength and Physical Activity in Children with IBD: Insights into Sarcopenia RiskECCO'25Year: 2025
Authors: Kasznár, E.(1);Karoliny, A.(1);Gombos, E.(1);Szentannay, J.(1);Szabó, A.(1);Dohos, D.(1);Bajzat, D.(1);Timár, Á.E.(1);Müller, K.(1)*;
(1)Heim Pál National Pediatric Institute, Gastroenterology and Nephrology, Budapest, Hungary;
P0860: Long-term outcomes of extended versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission: 3-year follow-up of the randomized controlled LADI trialECCO'25Year: 2025
Authors: Devillers, M.(1)*;van Lierop, L.(2);van Linschoten, R.(1);Jansen, F.(3);den Broeder, N.(4);de Jong, D.(3);Bodelier, A.(5);West, R.(6);Gisbertz, I.(7);Römkens, T.(8);Boekema, P.(9);Lutgens, M.(10);Mujagic, Z.(11);Wolfhagen, F.(12);de Boer, N.(13);Oldenburg, B.(14);van Bodegraven, A.(15);Mallant-Hent, R.(16);van der Meulen-de Jong, A.(17);ter Borg, P.(18);Braat, H.(19);Jansen, J.(20);Tan, A.(21);Jansen, S.(22);van der Woude, J.(1);de Vries, A.(1);Hoentjen, F.(2);
(1)Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(2)University of Alberta, Division of Gastroenterology, Edmonton, Canada;(3)Radboud University Medical Center, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(4)Sint Maartenskliniek, Department of Rheumatology, Nijmegen, The Netherlands;(5)Amphia Hospital, Department of Gastroenterology and Hepatology, Breda, The Netherlands;(6)Franciscus Gasthuis & Vlietland, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(7)Bernhoven Hospital, Department of Gastroenterology and Hepatology, Uden, The Netherlands;(8)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, 'S-Hertogenbosch, The Netherlands;(9)Maxima Medical Center, Department of Gastroenterology and Hepatology, Eindhoven, The Netherlands;(10)Elisabeth Twee Steden Ziekenhuis, Department of Gastroenterology and Hepatology, Tilburg, The Netherlands;(11)Maastricht University Medical Center +, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands;(12)Albert Schweitzer Hospital, Department of Gastroenterology and Hepatology, Dordrecht, The Netherlands;(13)Department of Gastroenterology and Hepatology- Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Center, Amsterdam, The Netherlands;(14)UMC Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(15)Zuyderland Medical Center, Department of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Sittard-Geleen/Heerlen, The Netherlands;(16)Flevoziekenhuis, Department of Gastroenterology and Hepatology, Almere, The Netherlands;(17)Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;(18)Ikazia hospital, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(19)Medisch Spectrum Twente, Department of Gastroenterology and Hepatology, Enschede, The Netherlands;(20)OLVG, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(21)CWZ Hospital, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(22)Reinier de Graaf Gasthuis, Department of Gastroenterology and Hepatology, Delft, The Netherlands;
References
1. van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, et al. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(4):343-55.
P0861: Comparative effectiveness and safety of ustekinumab versus anti-tumour necrosis Factor agents as first- or second-line biologics in Crohn´s disease: a real-world multicentric observational studyECCO'25Year: 2025
Authors: Ferreira, S.(1)*;Serafim Parra, R.(2);Yukie Sassaki, L.(3);Kurtz de Mello, M.(4);Luz Parente, J.M.(5);Bafutto, M.(6);Cancela Penna, F.G.(7);Penna Pinho, L.(7);de Sá Brito Fróes, R.(8);Tricarico Gasparetti Junior Gasparetti, N.L.(9);Andrade Chebli, L.(10);Tiburcio Alves Junior, A.J.(11);Firmino Nóbrega, F.J.(12);Botelho Quaresma, A.(13);Mattioli Nicollelli, G.(14);Galhardi Gasparini, R.(15);de Medeiros Dutra, R.(16);Oliveira Magro , D.(17);Gardere Camargo, M.(17);Palha Dias Parente, L.(18);Féres, O.(19);de Almeida Troncon, L.E.(20);Kotze, P.G.(21);Fonseca Chebli, J.M.(10);
(1)Hospital das Clínicas- Ribeirão Preto Medical School, Medicine, Ribeirão Preto, Brazil;(2)Hospital das Clínicas - Ribeirão Preto Medical School, Surgery and Anatomy, Ribeirão Preto, Brazil;(3)Medical School- Sao Paulo State University UNESP, Internal Medicine, Botucatu, Brazil;(4)University of Vale do Itajaí, Medicine, Itajaí, Brazil;(5)Health Science Center, Division of Gastroenterology of the Medicine Course at Federal University of Piauí, Teresina, Brazil;(6)Federal University of Goiás, Medicine, Goiânia, Brazil;(7)Alpha Institute - Federal University of Minas Gerais, Medicine, Belo Horizonte, Brazil;(8)Gastromed, Gastroenterology and Endoscopy, Rio de Janeiro, Brazil;(9)Hospital Vivalle Rede Dor, Medicine, São José dos Campos, Brazil;(10)Division of Gastroenterology - Federal University of Juiz de Fora, Medicine, Juiz de Fora, Brazil;(11)PUC-Campinas Medical School, Surgery, Campinas, Brazil;(12)Lauro Wanderley Hospital- Federal University of Paraíba, Gastroenterology, João Pessoa, Brazil;(13)Universidade do Oeste de Santa Catarina UNOESC, Surgery, Joaçaba, Brazil;(14)Hospital de Clínicas das UFPR, Surgery, Curitiba, Brazil;(15)Sete - Specialized Medical Center, Surgery and endoscopy, Marília, Brazil;(16)Medical School- Sao Paulo State University UNESP-, Internal Medicine, Botucatu, Brazil;(17)State University of Campinas UNICAMP, Surgery, Campinas, Brazil;(18)Hospital Municipal Dr. Moyses Deutsch, Medicine, São Paulo, Brazil;(19)Ribeirão Preto Medical School- University of São Paulo, Surgery and Anatomy, Ribeirão Preto, Brazil;(20)Ribeirão Preto Medical School- University of São Paulo, Medicine, Ribeirão Preto, Brazil;(21)Pontificia Universidade Católica do Paraná PUCPR, Health Sciences Postgraduate Program, Curitiba, Brazil;
P0862: Elderly-onset inflammatory bowel disease (IBD) differs in disease characteristics and treatment exposures from adult-onset IBDECCO'25Year: 2025
Authors: Granot, M.(1)*;Kopylov , U.(2); Nachum, N.(1);Krauthammer, A.(1);Tal, B.(1);Abitbol , C.M.(2);Ben-Horin, S.(2);Weiss, B.(1);Haberman, Y.(1);
(1)Sheba Medical Center- Tel-HaShomer, Pediatric Gastroenterology and Nutrition Unit, Ramat Gan, Israel;(2)Sheba Medical Center- Tel-HaShomer, Department of Gastroenterology, Ramat Gan, Israel;
P0863: Risk of colitis in patients with Inflammatory Bowel Disease exposed to checkpoint inhibitors – a national Danish cohort studyECCO'25Year: 2025
Authors: Dahl, E.(1)*;Christensen, K.R.(2);Jacobsen, H.A.(3);Anders , K.(4);Dige, A.(5);Svane, I.M.(4);Donia, M.(4);Bjerrum, J.T.(1);Seidelin, J.B.(6);
(1)Herlev University Hospital, Gastroenterology, Herlev, Denmark;(2)University of southern Denmark, Gastroenterology, Odense, Denmark;(3)Aalborg university hospital, gastroenterology, Aalborg, Denmark;(4)Herlev university hospital, Oncology, Herlev, Denmark;(5)Aarhus university hospital, Hepatology and gastroenterology, Aarhus, Denmark;(6)Rigshospitalet, digestive diseases- transplantation and general surgery, Copenhagen, Denmark;
P0864: Real-world effectiveness of upadacitinib for perianal Crohn’s disease: A multi-center retrospective studyECCO'25Year: 2025
Authors: Devi, J.(1);Quraishi, B.(2);Dev, B.(2);Kline, M.(3);Jaiprada, F.(1);Huang, K.(1);Khan, A.(4);Alanazi, S.(5);Seeraj , A.A.(5);Maas, L.(6);Jajoo, A.(6);Chowla, N.(7);Stone, M.(8);Patel, A.(9);Xu, A.(10);Shukla, R.(10);Bishu, S.(8);Johnson, A.L.(7);Parian, A.(6);Yarur, A.(4);McCurdy, J.(5);Mcdonald, B.D.(3);Wong, S.Y.(2);Deepak, P.(11)*;
(1)Washington University in St. Louis School of Medicine, Gastroenterology, St. Louis, United States;(2)Icahn School of Medicine at Mt. Sinai, Gastroenterology, New York City, United States;(3)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(4)Cedars Sinai Medical Center, Gastroenterology, Los Angeles, United States;(5)University of Ottawa, Gastroenterology, Ottawa, Canada;(6)Johns Hopkins University, Gastroenterology, Baltimore, United States;(7)College of Medicine Mayo Clinic, Gastroenterology, Rochester, United States;(8)University of Michigan, Gastroenterology, Ann Arbor, United States;(9)Brooke Army Medical Center, Gastroenterology, San Antonio, United States;(10)Baylor College of Medicine, Gastroenterology, Houston, United States;(11)Washington University School of Medicine in St. Louis, Gastroenterology, Saint Louis, United States;